title: Significance of cytomegalovirus infection in renal transplantation.
abstract: The aim of this study was to establish the relationship between vascular lesion chronic allograft nephropathy (CAN) and the presence of cytomegalovirus (CMV) in kidney transplanted patients. We studied 259 consecutive kidney transplant recipients with a minimum follow-up of 6 months; the induction immunosuppressive therapy included a calcineurin inhibitor, mycophenolate mofetil, steroids, and the use of an antilymphocyte serum if the patients developed delayed graft function. CMV early antigen detection (pp65) was performed on a weekly basis between days 30 and 90 post transplantation. Prophylactic treatment was administered in the donor +/recipient-risk group, and preemptive therapy delivered for positive antigenemia namely 3 days of intravenous [IV] gancyclovir [GCV] plus 11 days of oral therapy [in the case of infection], or 14 days of IV GCV [in the case of disease]). An acute kidney allograft rejection episode preceded CMV in 64.3% of the patients, and CMV preceded acute rejection in 35.7% of the cases. We conclude that CMV disease is an independent risk factor for CAN. CMV infection is probably associated with CAN, suggesting that the greater the viral load, the higher the risk of CAN. It may be advisable to perform universal prophylaxis to lower the viral load and CAN.
authors.affiliation: Renal Transplantation Unit, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain. rsola@fundacio-puigvert.es
authors.forename: R
authors.initials: R
authors.lastname: Solà
authors.forename: J M
authors.initials: JM
authors.lastname: Díaz
authors.forename: L
authors.initials: L
authors.lastname: Guirado
authors.forename: N
authors.initials: N
authors.lastname: Ravella
authors.forename: L
authors.initials: L
authors.lastname: Vila
authors.forename: Z
authors.initials: Z
authors.lastname: Sainz
authors.forename: I
authors.initials: I
authors.lastname: Gich
authors.forename: M
authors.initials: M
authors.lastname: Picazo
authors.forename: R
authors.initials: R
authors.lastname: García
authors.forename: E
authors.initials: E
authors.lastname: Abreu
authors.forename: F
authors.initials: F
authors.lastname: Ortiz
authors.forename: A
authors.initials: A
authors.lastname: Alcaraz
mesh_terms: D003586:Cytomegalovirus Infections / Q000453:epidemiology*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology* / Q000502:physiology; D015999:Multivariate Analysis; D012307:Risk Factors
chemical_list: D007166:Immunosuppressive Agents